Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 EX-3.1
- 3.2 EX-3.2
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 16.1 EX-16.1
- 21.1 EX-21.1
- 99.1 Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Changes in Registrant's Certifying Accountant; Changes in Control of Registrant; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Change in Shell Company Status; Financial Statements and Exhibits
- Download Excel data file
- View Excel data file
SABS similar filings
- 22 Nov 21 Financial Statements and Exhibits
- 22 Nov 21 SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
- 19 Nov 21 Entry into a Material Definitive Agreement
- 28 Oct 21 Entry into a Material Definitive Agreement
- 21 Oct 21 Submission of Matters to a Vote of Security Holders
- 13 Oct 21 Other Events
- 12 Oct 21 Entry into a Material Definitive Agreement
Filing view
External links
Exhibit 16.1
October 28, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by SAB Biotherapeutics, Inc. (formerly Big Cypress Acquisition Corp.), under Item 4.01 of its Form 8-K filed October 28, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on October 28, 2021, with the effective dismissal date of November 15, 2021. We are not in a position to agree or disagree with other statements of SAB Biotherapeutics, Inc. (formerly Big Cypress Acquisition Corp.) contained therein.
Very truly yours,
/s/ Marcum LLP | |
Marcum LLP |